Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...
5d
AZoLifeSciences on MSNBispecific antibodies for SARS-CoV-2 variant neutralizationBispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...
SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...
Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...
The following is a summary of “Annual variant-targeted vaccination to prevent severe COVID-19 disease in cohorts with vaccine-derived and hybrid immunity,” published in the March 2025 issue of ...
The virus that causes COVID-19 continues to mutate. Scientists say that's likely to continue indefinitely, and the virus will ...
According to a study of the COVICAT cohort, almost one in four people infected with SARS-CoV-2 suffered from long-COVID. Long ...
SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years.
Starting from April 8, people aged 65 and older, indigenous people aged 55 to 64, children younger than six months old and ...
Long COVID symptoms persisted for up to two years in more than half of the individuals who experienced the condition, according to new research published in BMC Medicine.
One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results